Dietary supplementation of Nile tilapia (Oreochromis niloticus) with ß-glucan and/or Bacillus coagulans: Synergistic impacts on performance, immune responses, redox status and expression of some related genes.

A 14-week feeding study was conducted to assess the effects of feed supplementation with prebiotics ß-glucan (BG group) and/or probiotics Bacillus coagulans (BC group) on O. niloticus growth performance, body analysis, intestinal structure, immunological response, and antioxidant status. The fish were equally divided into six groups, as follows: the fish group fed an un-supplemented diet served as a control group; the other fish groups were fed supplemented diets with 0.1 g ß-glucan kg-1; 1 g Bacillus coagulans kg-1; 2 g B. coagulans kg-1; 0.1 g ß-glucan combined with 1 g B. coagulans kg-1; 0.1 g ß-glucan combined with 2 g B. coagulans kg-1. The findings revealed that supplementing B. coagulans and the ß-glucan mixture improved growth performance and feed efficiency parameters (RGR and SGR) more than the other groups. The fish flesh analysis revealed increased crude protein and dry matter content and lower lipid and ash levels in the BG and BC supplemented groups than in the Control group. On the other hand, ß-glucan and B. coagulans supplementation significantly boosted antioxidant activity and immunological responses in serum as determined by CAT, MDA, lysozyme, and phagocytic activity. Dietary ß-glucan and B. coagulans supplementation remarkedly enhanced anterior intestine villus histomorphometry characteristics. Furthermore, B. coagulans, alone or in combination with ß-glucan, could reduce HSP70 and IL-1ß gene expression while increasing IL-8 and GH gene expression. According to the findings, B. coagulans and/or BG increased growth performance by increasing gut health and morphology. Furthermore, ß-glucan and B. coagulans supplementation enhanced Tilapia's body composition, immunological responses, and antioxidant status.

Trial for use nanoselenium particle with different dietary regime in Oreochromis niloticus and Mugil cephalus polyculture ponds: Growth efficiency, haematological, antioxidant, immunity and transcriptional analysis.

BACKGROUND: Fish farming is one of the most productive economies in the world. One of the essential goals in fish production is to minimize processing costs while maintaining and increasing the vital functions, weight and immunity of fish. OBJECTIVE: We conducted this study to explore nanoselenium (Nano-Se) particles in various feeding schemes. MATERIAL AND METHOD: Nano-Se particles incorporated in the basal diet at (0.5 mg/kg diet), and the fish was divided into six groups after adaptation as the follows: The first group was feed daily with a diet containing Nano-Se (0.5 mg/kg diet); the second group was exposed to a feeding programme in which it has day feeding followed by day of starvation with a diet containing Nano-Se (0.5 mg/kg diet); the third group was day feeding followed by 2 days of starvation; the fourth group served as a negative control group in which this group was continuous feeding with a basal diet without Nano-Se; the fifth group was day feeding with the basal diet followed by a day of starvation; and the sixth group was day feeding with basal diet followed by 2 days of starvation. RESULT: Our result revealed that Group 2 showed significant improvement in haematological parameters, red blood cells and haemoglobin with a substantial increase in total protein (p < 0.05) as well as lysosomal and phagocytic activity with considerable upregulation of growth hormone and insulin growth factor 1 in addition to markedly increase in the pro-inflammatory cytokines. Finally, this study offers the first-time dietary regime with Nano-Se supplementation that saves the feeding cost and increases fish welfare and growth.

Selenium Nanoparticles Act Potentially on the Growth Performance, Hemato-Biochemical Indices, Antioxidative, and Immune-Related Genes of European Seabass (Dicentrarchus labrax).

The current study investigated the role of selenium (Se) nanoparticles on the growth performance, hemato-biochemical indices, antioxidative, and immune-related genes of European seabass (Dicentrarchus labrax). Therefore, fish with initial weight of 20.53 ± 0.10 g/fish were fed diets with 0, 0.25, 0.5, and 1 mg Se nanoparticles/kg diet for 90 days. The final body weight, weight gain, and specific growth rate of fish fed dietary nano-Se varying levels were significantly higher than the control with the highest performances and lowest FCR in the group of fish fed nano-Se at 0.5 mg/kg. The values of Hb, PCV, RBCs, and WBCs were significantly higher in fish fed varying levels of Se nanoparticles than fish fed the basal diets. The values of total serum protein and globulin were significantly higher in fish fed varying levels of Se nanoparticles than fish fed the basal diets. Additionally, globulin had higher value in the group of fish fed 0.25 and 0.5 mg nano-Se/kg than fish fed 1 mg nano-Se/kg (P < 0.05). No significant alterations were observed on albumin, ALT, and AST variables (P > 0.05). Phagocytic index, phagocytic, lysozyme activities were significantly higher in fish fed varying levels of Se nanoparticles than fish fed the basal diets in a dose dependent manner (P < 0.05). Further, SOD activity had higher value in the group of fish fed 0.25 and 0.5 mg nano-Se/kg than fish fed 1 mg nano-Se/kg, whereas CAT was increased in the group of fish fed dietary 0.5 mg nano-Se/kg diet (P < 0.05). The level of MDA was significantly lowered by dietary nano-Se where the group of fish fed 0.25 mg/kg had the lowest level followed by those fed 0.5 and 1 mg/kg. The expression of GH, IGF-1, IL-8, and IL-1ß genes had the highest mRNA levels in the group of fish fed 0.25 and 0.5 mg/kg followed by those fed 1 mg/kg, whereas HSP70 was downregulated. Based on the overall results, Se nanoparticles are recommended at the rate of 0.5-1 mg/kg diet to maintain the optimal growth performance, hemato-biochemical indices, antioxidative status, and immune-related genes in European seabass.

Higher Performance and Safer Handling: Formulation Based on 2,2,2-Trinitroethyl Formate and Nitrocellulose.

A new, green propellant formulation based on the high-energy dense oxidizer (HEDO) 2,2,2-trinitroethyl formate (TNEF) and nitrocellulose (NC) was prepared and thermally investigated using non-isothermal thermogravimetric analysis (TGA) and differential scanning calorimetry (DSC). Scanning electron microscopy (SEM) was used to check the crystals of the oxidizer and the homogeneity of the new propellant formulation (NC-TNEF). The burning behavior of NC-TNEF was recorded by high-speed camera to observe the smoke produced. A high specific impulse (Is =257.4 s) was obtained from the characteristics calculation of the new propellant formulation by using EXPLO5_V6.03 software. The NC-TNEF mixture did not show any endothermic peak and its exothermic peak was at 204.6 °C, which means that a composite might be formed. The activation energy of the NC-TNEF was in the range of 184-190 kJ mol-1 . NC-TNEF has a higher performance and a lower hazard compared with the double-base propellant.

Environmentally safe (chlorine-free): new green propellant formulation based on 2,2,2-trinitroethyl-formate and HTPB.

A new green (chlorine-free) high energy dense oxidizer (HEDO) 2,2,2-trinitroethyl-formate (TNEF) and its propellant formulation based on the hydroxyl-terminated polybutadiene (HTPB) as a binder was prepared and studied. The new oxidizer TNEF was successfully prepared and characterized by nuclear magnetic resonance (NMR) and FTIR spectrometer. Scanning electron microscopy (SEM) was used to check the crystal morphology of the oxidizer. A high specific impulse (I s = 250.1 s) was obtained from the characteristics calculation of the new oxidizer instead of (I s = 156.9 s) for the commonly used ammonium perchlorate (AP) by using EXPLO5_V6.03 software. The burning behavior and the burning rate were determined by using a high speed camera. TNEF and the propellant formulations were studied by using nonisothermal thermogravimetric analysis (TGA) and the kinetic parameters of the studied samples were determined by using isoconversional (model-free) methods "Kissinger, Ozawa and Flynn-Wall (OFW) and Kissinger-Akahira-Sunose (KAS)". The results proved that the new oxidizer and its formulation based on HTPB have chlorine-free decomposition products and have higher performance characteristics than the traditional propellants.

The impact of a 600-mg loading dose of clopidogrel in diabetic and non-diabetic patients undergoing elective PCI.

BACKGROUND: High platelet reactivity (HPR) and suboptimal response to dual antiplatelet therapy (DAPT) may explain high recurrent rates of ischemic events in type 1 and 2 diabetes mellitus (DM) patients undergoing percutaneous coronary intervention (PCI). The aim of this study was to determine the effect of diabetes mellitus on clopidogrel activity in cardiac patients undergoing PCI. METHODS: This is an observational study. Patients were categorized according to DM status into diabetic group (N.=30) and non-diabetic group (N.=33). All patients received clopidogrel in a loading dose of 600 mg before PCI. Platelet function was assessed using light transmittance aggregometry (LTA) technique at baseline (before clopidogrel administration), 24 hour after clopidogrel loading dose administration and 7-10 days after PCI. All patients were followed up for at least one year after PCI for recurrence of acute cardiac events. RESULTS: There was no statistically significant difference between the two groups with respect to 10 µm adenosine diphosphate (ADP)-induced platelet aggregation measured at baseline (P=0.64), 24 hours after PCI (P=0.874), and 7-10 days after PCI (0.643). Diabetics were not significantly different from non-diabetics in terms of post-PCI acute stent thrombosis (P=0.945), sub-acute stent thrombosis (P=0.945), unstable angina (P=0.29) and cardiac death (P=0.64). There was a statistically significant difference between patients with and without post-PCI acute events regarding ADP aggregation measured 24 hours and 7-10 days after PCI. CONCLUSIONS: The use of a high loading dose of clopidogrel (600 mg) in patients undergoing elective PCI can overcome the significant increase in post-PCI platelet aggregation and rate of acute cardiac events induced by diabetes mellitus as co-morbidity in those patients.